What to Do If You're Currently on BPC-157 or TB-500

The 30-Second Answer

What Is Actually Happening

On July 23-24, 2026, the FDA's Pharmacy Compounding Advisory Committee will meet to review seven peptides, including BPC-157 and TB-500, and vote on whether they should be cleared for pharmacy compounding. The panel makes a recommendation; the FDA makes the final decision, and any real change after that goes through a formal rulemaking process that takes months.

Here is the part the headlines bury: these peptides were already removed from the FDA's restricted list back in April 2026. The July meeting is part of the path toward restoring formal compounding access, not toward taking it away. If you want the full breakdown of the regulatory picture, we wrote it up here: What the July 2026 FDA Peptide Panel Means for Patients. This article is narrower and more practical: what you, as a current user, should actually do.

What This Does NOT Mean

It does not mean your peptide is suddenly illegal. A meeting on a calendar does not change the law, and possessing a peptide your provider prescribed is not affected by an advisory vote.

It does not mean your prescription is canceled. A valid prescription filled by a licensed pharmacy stays valid. Nothing about July 23-24 reaches into your medicine cabinet.

It does not mean you need to act today. There is no deadline bearing down on you as a patient. The only July deadline that touches you is optional: the public comment window, if you choose to use it.

Your Action Plan

If you want a concrete checklist, here it is, in order.

1. Do not change anything on your own. Do not stop, restart, increase, or decrease your dose because of the news. Protocol changes belong with your prescribing provider.

2. Message your provider if you have questions. A quick note asking "does the July FDA meeting change anything for me?" is reasonable. The answer for most patients will be no, but your provider can speak to your specific case.

3. Keep your refills on their normal schedule. There is no need to rush, double up, or front-load orders. Order the way you normally would.

4. Do not buy from gray-market sources. If a "research chemical" site is telling you to stock up before a ban, that is a sales tactic, not safety advice. Skip it.

5. Optionally, submit a public comment. If you want a voice in the process, the FDA opened a docket for exactly that (details below).

Should You Stop?

This is the question driving most of the anxiety, so let us be direct: there is no regulatory reason to stop your therapy because of the July meeting, and the decision to pause or continue any treatment is one to make with your prescribing provider, not in response to a headline.

BPC-157 and TB-500 are not known to cause physical dependence or a withdrawal syndrome, so this is not a situation where stopping is dangerous in the way it can be with certain medications. But that is exactly why panic is unwarranted in either direction. If something about your protocol is on your mind, the right move is a conversation with your provider, who can weigh your goals, your history, and where you are in your protocol.

Your Prescription and Refills

A common worry is that the meeting will somehow freeze prescriptions or shut off refills overnight. It will not. The advisory vote is non-binding, and even a recommendation to change the rules would have to move through formal FDA rulemaking — a proposed rule, a public comment period, and a final rule — before anything practical shifts. That is a months-long process, not an overnight switch.

In the meantime, your provider can keep prescribing and a licensed pharmacy can keep compounding under the same framework that has been in place all along. If access ever does tighten down the road, your provider is the right person to help you navigate alternatives. The job right now is simply to stay on your normal schedule and stay in contact with your care team.

Should You Stockpile?

No, and this is worth spelling out because the impulse is so common. "Buy a year's worth before the ban" feels protective, but it pushes you toward exactly the riskiest behavior: bulk-buying from unregulated vendors that sell peptides as "research chemicals, not for human consumption." Those products carry no guarantee of identity, purity, or sterility — and during a period of regulatory churn, those are the sellers most aggressively using fear to move inventory.

There is also a practical problem: peptides have real storage and stability limits. A stockpile that degrades in your refrigerator is not protection, it is waste. The durable form of security is a relationship with a licensed provider and pharmacy, not a drawer full of vials from a website you cannot vet.

How Legitimate Access Works

The reason a real provider relationship is the safe harbor here is structural. When you get a peptide through a licensed provider and a 503A compounding pharmacy, the provider reviews your health history, the peptide is compounded in a sterile facility and tested for potency and sterility, the dose is matched to you, and there is a medical record and someone to call. None of that exists when you buy from a gray-market site.

That framework is also what carries your legal protection. Your access does not depend on which list a peptide sits on this month; it depends on the prescription-and-pharmacy structure around it, which is exactly what stays intact through the July meeting and whatever follows. If you want the longer explanation of the legal status, we cover it in Are Peptides Legal in 2026? and in Will the FDA Ban Peptides in 2026?.

How to Make Your Voice Heard

If sitting tight feels passive and you want to actually do something, there is a constructive option: the FDA opened a public docket for this review, and patient comments are part of the record the committee considers.

Frequently Asked Questions

Reviewed by Dr. Cory Mellon, MD · Last reviewed June 2026